Ending a decades-long wait, the US Food and Drug Administration (FDA) today approved the Amplatzer PFO Occluder device (St. Jude Medical) for recurrent stroke prevention in patients with a patent ...

With the approval of the AMPLATZER PFO Occluder, patients in the U.S. with a PFO who have suffered an ischemic stroke – a stroke resulting from blockages in the blood supply to the brain – will now ...

St. Jude Medical’s stroke-fighting heart occluder picked up FDA approval on Friday. The device had previously been available in the U.S. under a humanitarian device exemption, but was voluntarily ...

Ten years ago, my tennis partner suffered a stroke. He was a sixty-year-old at the time, working to move up into the top ten players in his age group. In the country! You could not have found a ...

Please provide your email address to receive an email when new articles are posted on . St. Jude Medical announced the FDA approved its transcatheter device for occlusion of patent foramen ovale. The ...

- Abbott's Talisman system seals an opening in the heart known as a "patent foramen ovale" (PFO) to prevent blood clots from passing from the right to the left side of the heart and on to the brain, ...

Two controversial trials testing PFO closure with the Amplatzer PFO Occluder (St. Jude Medical) in patients with cryptogenic stroke, first presented last fall at the TCT meeting, have now been ...

Abbott has launched its Amplatzer Tailsman PFO Occlosion System in Europe. The device is designed to treat people with a patent foramen ovale (PFO) who have had a stroke and are at risk of having ...

WASHINGTON — Final results of the RESPECT trial showed that percutaneous patent foramen ovale closure reduced the risk for recurrent stroke compared with guideline-directed medical therapy alone over ...

MIAMI – The Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) and PC Trial were both presented last week at TCT 2012 after ...

- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients ...